These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 28348885)
1. Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy. Mira F; Paulo M; Henriques F; Figueira J J Ophthalmol; 2017; 2017():5632634. PubMed ID: 28348885 [No Abstract] [Full Text] [Related]
2. [Anti-VEGF therapy for diabetic macular edema. From theory to clinical practice]. Fursova AZ; Chubar NV; Tarasov MS; Niculich IF; Vasilyeva MA; Gusarevich OG Vestn Oftalmol; 2018; 134(2):12-22. PubMed ID: 29771880 [TBL] [Abstract][Full Text] [Related]
3. Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Lim LS; Ng WY; Mathur R; Wong D; Wong EY; Yeo I; Cheung CM; Lee SY; Wong TY; Papakostas TD; Kim LA Clin Ophthalmol; 2015; 9():1715-8. PubMed ID: 26396494 [TBL] [Abstract][Full Text] [Related]
4. Effect of intravitreal aflibercept on recalcitrant diabetic macular edema. Klein KA; Cleary TS; Reichel E Int J Retina Vitreous; 2017; 3():16. PubMed ID: 28373914 [TBL] [Abstract][Full Text] [Related]
5. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Laiginhas R; Silva MI; Rosas V; Penas S; Fernandes VA; Rocha-Sousa A; Carneiro Â; Falcão-Reis F; Falcão MS Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):83-89. PubMed ID: 29082448 [TBL] [Abstract][Full Text] [Related]
6. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months]. Holbach B; Zeman F; Helbig H; Gamulescu MA Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192 [TBL] [Abstract][Full Text] [Related]
7. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab. Nixon DR; Flinn NA Clin Ophthalmol; 2018; 12():191-197. PubMed ID: 29403260 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis. Liu Y; Cheng J; Gao Y; Qin L; Min X; Zhang M Ann Transl Med; 2020 Mar; 8(6):382. PubMed ID: 32355826 [TBL] [Abstract][Full Text] [Related]
10. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema. Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058 [TBL] [Abstract][Full Text] [Related]
11. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema. Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365 [TBL] [Abstract][Full Text] [Related]
12. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs. Ibrahim WS; Eldaly ZH; Saleh MG; Rateb MF; Aldoghaimy AH Korean J Ophthalmol; 2019 Apr; 33(2):122-130. PubMed ID: 30977321 [TBL] [Abstract][Full Text] [Related]
13. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion. Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study. Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385 [No Abstract] [Full Text] [Related]
15. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept. Chen YY; Chang PY; Wang JK Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640 [TBL] [Abstract][Full Text] [Related]
16. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness. Shah CP; Heier JS Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice. Plaza-Ramos P; Borque E; García-Layana A PLoS One; 2019; 14(10):e0223793. PubMed ID: 31644594 [TBL] [Abstract][Full Text] [Related]
18. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry. Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration. Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583 [TBL] [Abstract][Full Text] [Related]
20. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Bahrami B; Hong T; Zhu M; Schlub TE; Chang A Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]